Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. [electronic resource]
Producer: 20161031Description: 44563-78 p. digitalISSN:- 1949-2553
- Angiogenesis Inhibitors -- pharmacology
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Aorta -- drug effects
- Breast Neoplasms -- blood supply
- Cell Proliferation -- drug effects
- Chick Embryo
- Chorioallantoic Membrane -- blood supply
- Dose-Response Relationship, Drug
- Female
- Human Umbilical Vein Endothelial Cells -- drug effects
- Humans
- Indoles -- pharmacology
- Isoflavones -- pharmacology
- MCF-7 Cells
- Male
- Mice, Inbred BALB C
- Mice, Nude
- Neovascularization, Pathologic
- Neovascularization, Physiologic -- drug effects
- Phosphorylation
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-akt -- metabolism
- Pyrroles -- pharmacology
- Rats, Sprague-Dawley
- Receptor, Fibroblast Growth Factor, Type 2 -- antagonists & inhibitors
- STAT3 Transcription Factor -- metabolism
- Signal Transduction -- drug effects
- Sunitinib
- Time Factors
- Tumor Burden -- drug effects
- Vascular Endothelial Growth Factor Receptor-2 -- antagonists & inhibitors
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.